Investigating Systemic and Local Vascular Responses to Apelin in the Context of Renin-angiotensin Upregulation

Investigating the Interaction of Apelin and Systemic Angiotensin II Peripheral Resistance Vessels and Systemic Haemodynamics in Vivo in Man

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00901719

Enrollment

Registered

2009-05-14

Start date

2010-04-30

Completion date

2010-05-31

Last updated

2010-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Disease, Heart Failure, Vasodilatation

Keywords

Renin angiotensin system, Apelin, Cardiac output, Vasodilatation

Brief summary

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease. Two of the main actions of apelin are to increase the pumping ability of the heart and cause blood vessels to relax. The investigators wish to assess if these actions are altered in the setting of normal renin-angiotensin activation and increased renin-angiotensin activity.

Interventions

DRUGApelin

Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.

DRUGAcetylcholine

Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min

DRUGSodium nitroprusside

Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min

DRUGSystemic apelin infusion

Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Months to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* \>18yr

Exclusion criteria

* Lack of informed consent * Age \< 18 years, * Current involvement in other research studies, * Systolic blood pressure \>190 mmHg or \<100 mmHg * Malignant arrhythmias * Renal or hepatic failure * Haemodynamically significant aortic stenosis * Severe or significant co morbidity * Women of childbearing potential. * Any regular medication * Previous history of any cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Change in cardiac output	12 months
Change in apelin mediated vasodilatation	12 months

Secondary

Measure	Time frame
Change in systemic haemodynamics	12 months
Change in relevant neurohumoral hormones	12 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026